Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26507122 | 0.76 | MAPT (0.35) | TSHRTDP1ALDH1A1GLAHSD17B10 | |
| SCHEMBL7390984 | 0.73 | TSHR (0.44) | TSHRSMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL27918543 | 0.70 | ALDH1A1 (0.58) | TSHRSMN1; SMN2TDP1ALDH1A1HSD17B10 | |
| SCHEMBL6962624 | 0.70 | TSHR (0.41) | TSHRSMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL16971060 | 0.69 | SMN1; SMN2 (0.41) | TSHRSMN1; SMN2TDP1ALDH1A1GLA | |
| SCHEMBL11516735 | 0.69 | TSHR (0.44) | TSHRSMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL26352789 | 0.69 | TSHR (0.49) | TSHRSMN1; SMN2ALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL12190659 | 0.69 | ATM (0.47) | TSHRSMN1; SMN2TDP1ALDH1A1LMNA | |
| SCHEMBL3192674 | 0.68 | TSHR (0.65) | TSHRSMN1; SMN2TDP1ALDH1A1L3MBTL1 | |
| SCHEMBL10763450 | 0.68 | ALDH1A1 (0.40) | TSHRTDP1ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4314005-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-01-18 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-10-13 | — | — | US | disclosed |
| WO-2022204108-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20240018182-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | TSHR 193/4885SMN1; SMN2 4255/4885TDP1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.